A Lyme disease vaccine is in its final clinical trial : NPR
A new Lyme disease vaccine, VLA15, is in its final clinical trial phase, aiming to protect people aged five and up. Developed by Pfizer and Valneva, it targets a protein of the Borrelia bacteria, omitting a region linked to past adverse reactions. If successful, it could seek approval by 2025, offering a new defense against the spreading disease.
Reference News
A Lyme disease vaccine is in its final clinical trial : NPR
A new Lyme disease vaccine, VLA15, is in its final clinical trial phase, aiming to protect people aged five and up. Developed by Pfizer and Valneva, it targets a protein of the Borrelia bacteria, omitting a region linked to past adverse reactions. If successful, it could seek approval by 2025, offering a new defense against the spreading disease.